What Medications Are GLP-1? A Complete Guide to GLP-1 Receptor Agonists

In 2023, a landmark review published in Advances in Therapy reshaped how clinicians think about obesity pharmacotherapy. The authors — Moore, Malone, VanValkenburg and colleagues — examined the full landscape of anti-obesity medications and concluded that GLP-1 receptor agonists represent a genuinely new category of treatment, one capable of lowering HbA1c, reducing body weight, and improving a constellation of metabolic comorbidities simultaneously. That kind of multi-system impact is rare in pharmacology, and it explains why GLP-1 medications have moved from obscure diabetes drugs to some of the most-discussed compounds in modern medicine almost overnight.

But what exactly are these medications? How do they work, which ones are FDA-approved, and who actually benefits from them? If you’ve seen the headlines and wondered what’s underneath them, here’s the clinical reality — explained plainly.

Understanding What GLP-1 Medications Actually Are

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces in response to eating. When food hits the small intestine, GLP-1 is released and begins orchestrating a coordinated metabolic response: it signals the pancreas to release insulin, suppresses glucagon (a hormone that raises blood sugar), slows gastric emptying so nutrients absorb more gradually, and — critically — travels to the hypothalamus in the brain to reduce appetite and increase satiety. In a healthy person, this hormone is part of the feedback loop that tells you when you’ve had enough to eat.

GLP-1 receptor agonists (GLP-1RAs) are synthetic compounds engineered to mimic or amplify this natural hormone. They bind to the same receptors that native GLP-1 activates, but they’re designed to resist rapid degradation — meaning they stay active in the body far longer than the hormone your gut produces. Depending on the specific medication, dosing can range from daily injections to once-weekly subcutaneous administration. As explains, GLP-1RA therapy was originally developed to treat type 2 diabetes, but the pronounced weight reduction observed in clinical trials drove an entirely new therapeutic indication: obesity management.

The medications in this class aren’t identical. They differ in molecular structure, half-life, dosing schedule, approved indications, and clinical evidence base. Understanding those differences matters if you’re trying to make sense of what your doctor is prescribing — or what you’ve been reading about online.

Semaglutide is currently the most clinically prominent GLP-1RA. It’s available under three brand names with distinct applications. Ozempic (semaglutide 0.5–2 mg, once weekly subcutaneous injection) carries FDA approval for type 2 diabetes management and cardiovascular risk reduction. Wegovy (semaglutide 2.4 mg, once weekly) is FDA-approved specifically for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition. Rybelsus is an oral formulation approved for type 2 diabetes — the first GLP-1RA available in pill form. As Carboni, Woessner, Martini and colleagues noted in the Journal of Drugs in Dermatology, only Wegovy carries formal FDA approval for weight loss — a distinction that matters clinically even as other formulations are increasingly used off-label.

Liraglutide was the first GLP-1RA approved for obesity treatment. Sold as Victoza for diabetes and Saxenda for weight management, liraglutide requires a daily injection rather than weekly. It was a significant milestone, but head-to-head data has consistently shown semaglutide’s superior efficacy. A randomized, double-blind phase 2 trial by O’Neil, Birkenfeld, McGowan and colleagues directly compared semaglutide to liraglutide and placebo in 957 adults with obesity. Semaglutide produced clinically relevant weight loss at all doses tested over 52 weeks, consistently outperforming both placebo and liraglutide — establishing a clear efficacy hierarchy within the class.

Tirzepatide (brand name Mounjaro for diabetes, Zepbound for obesity) is technically a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. While not a pure GLP-1RA, it’s often discussed in the same category because of mechanistic overlap and similar clinical applications. Early trial data suggests even greater weight loss than semaglutide alone, though long-term comparative data continues to accumulate.

Older GLP-1RAs still in use include exenatide (Byetta and Bydureon) and dulaglutide (Trulicity), both primarily used for type 2 diabetes. These carry less weight-loss-specific evidence than semaglutide or liraglutide and are generally not the first choice when weight management is the primary goal.

What the Clinical Evidence Actually Shows

The efficacy data for semaglutide — the most studied of the modern GLP-1RAs — is genuinely impressive by pharmaceutical standards. A 2025 Cochrane systematic review by Bracchiglione, Meza, Franco and colleagues pooled data from 18 randomized controlled trials involving nearly 28,000 participants. At medium-term follow-up (6 to 17 months), semaglutide produced a mean body weight reduction of 10.73% compared to placebo — high-certainty evidence by GRADE standards. At long-term follow-up (around 26 months), the effect held: approximately 11% mean weight reduction, with more than 2.7 times as many participants achieving at least 5% weight loss compared to those on placebo.

That 5–15% weight loss threshold is clinically significant. As reductions in that range are associated with meaningful improvements in blood pressure, glycemic control, lipid profiles, sleep apnea severity, and joint loading. These aren’t cosmetic changes — they’re metabolic shifts with downstream consequences on cardiovascular and all-cause mortality risk.

The Cochrane review also showed semaglutide likely reduces major adverse cardiovascular events (MACE) and mortality compared to placebo, though these findings carry low-to-moderate certainty given study design limitations and the fact that most trials were manufacturer-funded. Adverse events are real: nausea, vomiting, diarrhea, and constipation are the most commonly reported, typically occurring early in treatment and improving as the body adjusts. Adverse events leading to withdrawal were more common with semaglutide than placebo, particularly in long-term trials — a clinically relevant consideration for anyone weighing the commitment.

The weight loss mechanism isn’t complicated to understand, even if the pharmacology is. These drugs reduce how much you want to eat, make you feel full faster, and slow the rate at which your stomach empties — meaning meals have more lasting satiety effect. For men who’ve struggled with appetite regulation despite consistent training and clean eating, that neurohormonal recalibration can be the difference between sustained progress and chronic frustration. But the drugs don’t replace the fundamentals. Protein intake, resistance training, sleep, and stress management remain non-negotiable if the goal is to lose fat while preserving the muscle mass that defines long-term metabolic health.

The Takeaway

GLP-1 receptor agonists — semaglutide, liraglutide, and their class peers — are among the most rigorously studied weight management tools in modern medicine. They work by amplifying a natural hormonal signaling pathway, and the weight loss data behind them, particularly for semaglutide, meets a high evidentiary bar. They are not magic. They require lifestyle scaffolding to produce optimal results, they carry real side effects, and their benefits appear to require continued use to be maintained. But for men with significant metabolic burden — elevated BMI, insulin resistance, type 2 diabetes, or cardiovascular risk — the evidence increasingly positions GLP-1 medications as a legitimate clinical tool, not a shortcut. Understanding what these drugs are, how they differ, and what the research actually says is the first step to making an informed decision about whether they belong in your approach.